Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 1,541 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 1,541 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total value of $235,572.67. Following the completion of the transaction, the chief executive officer now owns 136,778 shares in the company, valued at approximately $20,909,252.86. This trade represents a 1.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Kyle Gano also recently made the following trade(s):

• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00.

Neurocrine Biosciences Trading Down 0.8 %

NBIX opened at $151.20 on Thursday. The stock’s 50-day moving average price is $137.92 and its 200 day moving average price is $131.51. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The firm has a market cap of $15.31 billion, a price-to-earnings ratio of 40.54 and a beta of 0.33.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the business. State Street Corp increased its stake in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares during the period. Geode Capital Management LLC grew its stake in Neurocrine Biosciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock worth $213,773,000 after purchasing an additional 39,610 shares in the last quarter. Braidwell LP grew its position in shares of Neurocrine Biosciences by 20.9% during the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after buying an additional 158,665 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Neurocrine Biosciences by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 870,290 shares of the company’s stock worth $118,795,000 after buying an additional 12,040 shares during the period. Finally, Jennison Associates LLC lifted its stake in Neurocrine Biosciences by 145.1% in the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock worth $112,025,000 after acquiring an additional 485,894 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Piper Sandler reiterated an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Wedbush reiterated an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $166.85.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.